Tags

Type your tag names separated by a space and hit enter

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.
Viruses. 2020 01 20; 12(1)V

Abstract

Middle East respiratory syndrome (MERS) is an acute, high-mortality-rate, severe infectious disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe respiratory diseases. The continuous spread and great pandemic potential of MERS-CoV make it necessarily important to develop effective vaccines. We previously demonstrated that the application of Gram-positive enhancer matrix (GEM) particles as a bacterial vector displaying the MERS-CoV receptor-binding domain (RBD) is a very promising MERS vaccine candidate that is capable of producing potential neutralization antibodies. We have also used the rabies virus (RV) as a viral vector to design a recombinant vaccine by expressing the MERS-CoV S1 (spike) protein on the surface of the RV. In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can induce remarkably higher antibody response, even at a very low dose of 1 µg. These results indicate that vaccines constructed using different vaccine vector platforms for the same pathogen have different rates and trends in humoral and cellular immune responses in the same animal model. This discovery not only provides more alternative vaccine development platforms for MERS-CoV vaccine development, but also provides a theoretical basis for our future selection of vaccine vector platforms for other specific pathogens.

Authors+Show Affiliations

College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China. Animal Science and Technology College, Jilin Agricultural University, Changchun 130118, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China. Animal Science and Technology College, Jilin Agricultural University, Changchun 130118, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China. College of Animal Science and Technology, Shihezi University, Shihezi 832003, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China. Animal Science and Technology College, Jilin Agricultural University, Changchun 130118, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.College of Veterinary Medicine, Jilin University, Changchun 130062, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China. Animal Science and Technology College, Jilin Agricultural University, Changchun 130118, China. College of Animal Science and Technology, Shihezi University, Shihezi 832003, China. College of Veterinary Medicine, Jilin University, Changchun 130062, China. Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou 225009, China.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31968702

Citation

Li, Entao, et al. "Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived From Two Different Vectors in Mice." Viruses, vol. 12, no. 1, 2020.
Li E, Yan F, Huang P, et al. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice. Viruses. 2020;12(1).
Li, E., Yan, F., Huang, P., Chi, H., Xu, S., Li, G., Liu, C., Feng, N., Wang, H., Zhao, Y., Yang, S., & Xia, X. (2020). Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice. Viruses, 12(1). https://doi.org/10.3390/v12010125
Li E, et al. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived From Two Different Vectors in Mice. Viruses. 2020 01 20;12(1) PubMed PMID: 31968702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice. AU - Li,Entao, AU - Yan,Feihu, AU - Huang,Pei, AU - Chi,Hang, AU - Xu,Shengnan, AU - Li,Guohua, AU - Liu,Chuanyu, AU - Feng,Na, AU - Wang,Hualei, AU - Zhao,Yongkun, AU - Yang,Songtao, AU - Xia,Xianzhu, Y1 - 2020/01/20/ PY - 2019/12/13/received PY - 2020/01/15/revised PY - 2020/01/17/accepted PY - 2020/1/24/entrez PY - 2020/1/24/pubmed PY - 2020/9/22/medline KW - MERS-CoV KW - bacterium-like particle KW - immune response KW - recombinant rabies virus JF - Viruses JO - Viruses VL - 12 IS - 1 N2 - Middle East respiratory syndrome (MERS) is an acute, high-mortality-rate, severe infectious disease caused by an emerging MERS coronavirus (MERS-CoV) that causes severe respiratory diseases. The continuous spread and great pandemic potential of MERS-CoV make it necessarily important to develop effective vaccines. We previously demonstrated that the application of Gram-positive enhancer matrix (GEM) particles as a bacterial vector displaying the MERS-CoV receptor-binding domain (RBD) is a very promising MERS vaccine candidate that is capable of producing potential neutralization antibodies. We have also used the rabies virus (RV) as a viral vector to design a recombinant vaccine by expressing the MERS-CoV S1 (spike) protein on the surface of the RV. In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can induce remarkably higher antibody response, even at a very low dose of 1 µg. These results indicate that vaccines constructed using different vaccine vector platforms for the same pathogen have different rates and trends in humoral and cellular immune responses in the same animal model. This discovery not only provides more alternative vaccine development platforms for MERS-CoV vaccine development, but also provides a theoretical basis for our future selection of vaccine vector platforms for other specific pathogens. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/31968702/Characterization_of_the_Immune_Response_of_MERS_CoV_Vaccine_Candidates_Derived_from_Two_Different_Vectors_in_Mice_ L2 - https://www.mdpi.com/resolver?pii=v12010125 DB - PRIME DP - Unbound Medicine ER -